Articles tagged "Immunosuppression"

2019 American Transplant Congress
How Well Do Kidney Transplant Patients Understand Their Medications and Does Real-Time Assessment of Knowledge Improve Retention of Information?
B. Clark¹, B. Sirandas¹, T. Larson², A. Carlson¹, C. Truax¹, D. D. Ramirez¹, L. Smith¹, I. Hall¹
¹University of Utah Health, Salt Lake City, UT, ²Henry Ford Hospital, Detroit, MI
*Purpose: This study aims to evaluate the impact that early formal assessment and reteaching have on patient medication knowledge after renal transplant.*Methods: This was a…
2019 American Transplant Congress
Clinical Utility of a Pharmacogenomic Testing Tool among Kidney Transplant Recipients
S. LeCorchick, L. Lindberg, W. Stapley, S. Anand, D. Morris, T. Srinivas
Kidney/Pancreas Transplant Program, Intermountain Medical Center, Murray, UT
*Purpose: Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is the cornerstone of clinical workflow in the transplant clinic. We report on the clinical implementation of,…
2019 American Transplant Congress
Clinical Trial of Allogeneic Islet Transplantation in the Treatment of Diabetes after Renal Transplantation
W. liang, M. Hu, G. Peng, D. Zhou, C. Zeng, W. Zhou, q. Ye, Z. Wang
Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases, Wuhan, China
*Purpose: Diabetes after renal transplantation is one of the most serious complications after renal transplantation. It has a serious impact to the survival of kidney…
2019 American Transplant Congress
Impact of Steroid-Free Protocol on Incidence of Posttransplantation Diabetes Mellitus: A Prospective, Randomized, Multicenter, Open-Label, Controlled Trial in Renal Transplant Recipients
J. Ekberg¹, S. Baid-Agrawal¹, B. Jespersen², R. Källén³, E. Rafael³, K. Skov², P. Lindnér¹
¹Institute of Clinical Sciences, Transplant Institute, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Department of Nephrology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Transplantation, Skane University Hospital, Malmoe, Sweden
*Purpose: Comparison of two immunosuppressive protocols, steroid-free with antithymocyte globulin (ATG) induction, and steroid containing with basiliximab induction, regarding the incidence of PTDM, one year…
2019 American Transplant Congress
Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Interstitial Fibrosis and Tubular Atrophy
G. Gupta¹, D. Kumar¹, M. Raynaud², A. Loupy², J. Chang³, J. Reeve³, P. Sanghi¹, I. Yakubu¹, L. Kamal¹, M. Levy¹, C. Bhati¹, P. Kimball¹, A. King¹, H. Massey¹, P. Halloran³
¹Virginia Commonwealth University, Richmond, VA, ²Paris Transplant Group, Paris, France, ³Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada
*Purpose: Prior studies on the conversion of tacrolimus (Calcineurin Inhibitor; CNI) to belatacept have been limited in scope due to either the absence of, post-conversion…
2019 American Transplant Congress
A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation: A Multicenter Study
L. Coromina¹, S. Shah², B. Xervos³, M. Zimmerman⁴, K. Sasaki¹, T. Diago¹, K. Hashimoto¹, F. Aucejo¹, m. Fujiki¹, H. Block-Beach¹, A. Patterson², C. Miller¹, C. Quintini¹, B. Eghtesad¹
¹The Cleveland Clinic, Cleveland, OH, ²University of Cincinnati, Cincinnati, OH, ³The Cleveland Clinic, Weston, FL, ⁴Medical College of Wisconsin, Milwaukee, WI
*Purpose: Thymoglobulin® (r-ATG) has been used as induction therapy in liver transplantation (LT). No prospective, randomized, controlled, trial (RCT) has been performed to evaluate effect…
2019 American Transplant Congress
The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation
T. Hiramitsu, T. Tomosugi, K. Futamura, M. Okada, M. Tsujita, T. Ichimori, N. Goto, S. Narumi, Y. Watarai
Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan
*Purpose: De novo DSA was demonstrated as a cause of chronic AMR, leading to worse graft survival. New strategies to treat chronic AMR have been…
2019 American Transplant Congress
Everolimus/Low Tacrolimus Exposure versus Sodium Mycophenolate/Standard Tacrolimus for the Elderly Kidney Transplant Recipient. A 4-y Follow-Up of the nEverOld Trial
E. David-Neto, F. Agena, F. J. Paula, N. Z. Galante, D. S. David, F. Ramos, A. K. Triboni, P. Romano, P. A. Ebner, V. Coelho, M. Altona, R. Falci, A. Piovesan, W. C. Nahas
Renal Transplantation Service, Hospital das Clínicas - University of São Paulo School of Medicine, Sao Paulo, Brazil
*Purpose: The standard immunosuppressive regimen used for younger patients may not be adequate for the elderly cohort.*Methods: The nEverOld is a prospective, single-center, randomized trial…
2019 American Transplant Congress
Early Rejection Outcomes with IL-2 vs. ATG Induction among Kidney Transplant Recipients Induction Differences with Early Steroid Withdrawal
C. Burelli, A. Szczepanik, K. Yadav, E. Sanchez, M. Debroy, V. Humphreville, J. Rabets, A. Padiyar, N. Sarabu, A. Jittirat, A. Palanisamy, K. Chavin
University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: Early steroid withdrawal in kidney transplant (Ktx) patients is controversial and has demonstrated an increased risk of acute rejection with similar long-term outcomes. Data…
2019 American Transplant Congress
Alemtuzumab versus Antithymocyte Globulin Induction Immunosuppression in Highly Sensitized Kidney Transplant Recipients
A. Brueckner¹, E. Yanqui¹, C. Truong¹, R. Baliga², L. Bowman¹
¹Tampa General Hospital, Tampa, FL, ²Florida Kidney Physicians, Tampa, FL
*Purpose: Lymphocyte depleting agents such as rabbit anti-thymocyte globulin (rATG) and alemtuzumab are used for induction in highly sensitized (PRA ≥30%) kidney transplant recipients (KTRs).…